Information for Providers

Aspira Women’s Health is Dedicated to Transforming Women’s Gynecologic Health, Starting with Ovarian Cancer and Endometriosis

Order Test Kits

Redefining Adnexal Mass Management with Precise Care 

Complementing your adnexal mass protocol, OvaWatch® and Ova1Plus® offer an individualized approach to risk assessment, to help ensure the right patient receives the right treatment at the right time.

Learn about Our Tests
Which Test Should I Use?
Proven Performance
Learn About Our Services
Black woman, doctor and senior patient with tablet, results and listen for health planning, advice or cancer. African medic, mobile touchscreen and healthcare with trust, tech and support in hospital.

Our OvaSuiteSM Portfolio of Products

Our non-invasive blood tests offers precise tools to inform ovarian care, helping providers enhance confidence in their medical management plans and triage specialist referrals more efficiently. 

Aspira_OVAWatch(R) logo 1

Planned for Clinical Management

  • For adnexal masses initially evaluated as indeterminate or benign
  • Negative Predictive Value of over 99%1
  • Longitudinal monitoring feature to help providers track risk over time
Learn More
Ova1 plus

Planned for Surgical Management

  • For adnexal masses that are planned for surgery
  • Ova1® has a greater than 96% sensitivity with clinical assessment2
  • Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score

Ova1Plus is a reflex process: Ova1® is performed3 first. If an intermediate risk is detected, Overa® is automatically performed.

Learn More

"My experience as a gynecologic oncologist has shown that OvaWatch and Ova1 are invaluable tools for patient care. These tests allow for stratification and timely triage of high-risk patients to specialist care. By using these tools, we ensure that we are treating the right patients at the right time, enhancing patient outcomes and optimizing medical resource allocation."

- Dr. Leo B Twiggs, MD, Gyn Onc 

"The usage of CA-125 with the standard ACOG cutoff in the African American population shows a sensitivity of only 33.3% in the detection of malignancy. When compared with using Ova1 or OvaWatch, we see the sensitivity increase to 79.2% which is absolutely amazing and definitely a clinical tool you want access to in your offices."

- Dr. Tamika L. Sea, MD, FACOG 

Watch This Video to Learn Which Test Is Best for Your Patient

Download the Clinical Triage for Adnexal Mass Guide

How It Works

BEFORE
DURING
AFTER

BEFORE THE TEST

Single blood draw, performed in healthcare provider's office or partner laboratories

DURING THE TEST

Proprietary algorithms incorporate patient features and levels of up to 7 biomarkers

AFTER THE TEST

Results include risk score, ovarian cancer risk assessment, and CA-125 result

Order Test Kits

Our Services

Test Kits that are completely free to order for physicians and can be stored in office for up to 1 year

Rapid results in about 48 hours

Easy-to-read reports with risk score and relevant individual biomarkers

Access to clinical experts for peer to peer consults

Experienced, responsive field and customer service teams

AWH_TestKit

Price Transparency & Financial Assistance to Patients

We are committed to making tests available to all women who need them. Covered by Medicare, Medicaid, and commercial insurance in many states. Cash pay is $295 per test. Financial assistance and payment plans are available for qualifying patients.

Connect with us to learn more or to order test kits

PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.

OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.